Stem cells in tumor angiogenesis

Journal of Molecular and Cellular Cardiology

Volumn 50, Issue 2, 2011, Pages 290-295

  Fang, Shentong ^a   Salven, Petri ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Angiogenesis; Cancer; Endothelial cell; Hematopoietic cell; Precursor; Progenitor; Stem cells

Indexed keywords

ANGIOPOIETIN RECEPTOR;

ADULT STEM CELL; BONE MARROW; CANCER GROWTH; CANCER INFILTRATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL STIMULATION; CELL SUBPOPULATION; DENDRITIC CELL; ENDOTHELIAL PROGENITOR CELL; EOSINOPHIL; EXTRACELLULAR MATRIX; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL; HEMOSTASIS; HUMAN; MAST CELL; MESENCHYMAL STEM CELL; MESENCHYME CELL; MONONUCLEAR CELL; MYELOID DERIVED SUPPRESSOR CELL; NEUTROPHIL; NONHUMAN; PARACRINE SIGNALING; PATHOPHYSIOLOGY; PERICYTE; PERICYTE PROGENITOR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; STROMA CELL; SUPPRESSOR CELL; THROMBOCYTE FUNCTION; TISSUE SPECIFICITY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIAL STEM CELL;

ANIMALS; CELL DIFFERENTIATION; ENDOTHELIAL CELLS; HEMATOPOIETIC STEM CELLS; HUMANS; MESENCHYMAL STEM CELLS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PARACRINE COMMUNICATION; PERICYTES; STEM CELLS;

EID: 79151480915     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2010.10.024     Document Type: Review

References (122)

1. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003, 9(6):653-660.
2. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005, 438(7070):932-936.
3. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285(21):1182-1186.
4. Crawford Y., Ferrara N. Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. Trends Pharmacol Sci 2009, 30(12):624-630.
5. Shojaei F., Ferrara N. Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. Cancer Res 2008, 68(14):5501-5504.
6. Murdoch C., et al. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008, 8(8):618-631.
7. Folkman J. What is the role of endothelial cells in angiogenesis?. Lab Invest 1984, 51(6):601-604.
8. Folkman J., Shing Y. Angiogenesis. J Biol Chem 1992, 267:10931-10934.
9. Asahara T., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275(5302):964-967.
10. Lyden D., et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001, 7(11):1194-1201.
11. Nolan D.J., et al. Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev 2007, 21(12):1546-1558.
12. Shaked Y., et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006, 313(5794):1785-1787.
13. Garcia-Barros M., et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003, 300(5622):1155-1159.
14. De Palma M., et al. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med 2003, 9(6):789-795.
15. Machein M.R., et al. Minor contribution of bone marrow-derived endothelial progenitors to the vascularization of murine gliomas. Brain Pathol 2003, 13(4):582-597.
16. Voswinckel R., et al. Circulating vascular progenitor cells do not contribute to compensatory lung growth. Circ Res 2003, 93(4):372-379.
17. Ziegelhoeffer T., et al. Bone marrow-derived cells do not incorporate into the adult growing vasculature. Circ Res 2004, 94(2):230-238.
18. Gothert J.R., et al. Genetically tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to tumor endothelium. Blood 2004, 104(6):1769-1777.
19. Rajantie I., et al. Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood 2004, 104(7):2084-2086.
20. De Palma M., et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005, 8(3):211-226.
21. Shinde Patil V.R., et al. Bone marrow-derived lin(-)c-kit(+)Sca-1+ stem cells do not contribute to vasculogenesis in Lewis lung carcinoma. Neoplasia 2005, 7(3):234-240.
22. Peters B.A., et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 2005, 11(3):261-262.
23. Ahn G.O., Brown J.M. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 2008, 13(3):193-205.
24. Purhonen S., et al. Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc Natl Acad Sci USA 2008, 105(18):6620-6625.
25. Salven P., et al. Reply to Kerbel et al.: EPCs are again claimed to be essential in yet other models despite the irreproducibility of the original experiments introducing them. Proc Natl Acad Sci 2008, 105(34):E55-E.
26. Perry T.E., et al. Bone marrow-derived cells do not repair endothelium in a mouse model of chronic endothelial cell dysfunction. Cardiovasc Res 2009, 84(2):317-325.
27. Iivanainen E., et al. The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels. Microvasc Res 2009, 78(3):278-285.
28. Wickersheim A., et al. Endothelial progenitor cells do not contribute to tumor endothelium in primary and metastatic tumors. Int J Cancer 2009, 125(8):1771-1777.
29. Hagensen M.K., et al. Circulating endothelial progenitor cells do not contribute to plaque endothelium in murine atherosclerosis. Circulation 2010, 121(7):898-905.
30. Horrevoets A.J. Angiogenic monocytes: another colorful blow to endothelial progenitors. Am J Pathol 2009, 174(5):1594-1596.
31. Kim S.J., et al. Circulating monocytes expressing CD31: implications for acute and chronic angiogenesis. Am J Pathol 2009, 174(5):1972-1980.
32. Kozin S.V., et al. Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. Cancer Res 2010, 70(14):5679-5685.
33. Rehman J., et al. Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 2003, 107(8):1164-1169.
34. Rohde E., et al. Blood monocytes mimic endothelial progenitor cells. Stem Cells 2006, 24(2):357-367.
35. Case J., et al. Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol 2007, 35(7):1109-1118.
36. Yoder M.C., et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007, 109(5):1801-1809.
37. Desai A., et al. Microarray-based characterization of a colony assay used to investigate endothelial progenitor cells and relevance to endothelial function in humans. Arterioscler Thromb Vasc Biol 2009, 29(1):121-127.
38. Yoder M.C. Defining human endothelial progenitor cells. J Thromb Haemost 2009, 7(Suppl. 1):49-52.
39. Yoder M.C., Ingram D.A. The definition of EPCs and other bone marrow cells contributing to neoangiogenesis and tumor growth: is there common ground for understanding the roles of numerous marrow-derived cells in the neoangiogenic process-. Biochim Biophys Acta 2009, 1796(1):50-54.
40. Coffelt S.B., Hughes R., Lewis C.E. Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim Biophys Acta 2009, 1796(1):11-18.
41. Jain R.K., Duda D.G. Role of bone marrow-derived cells in tumor angiogenesis and treatment. Cancer Cell 2003, 3(6):515-516.
42. Grunewald M., et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 2006, 124(1):175-189.
43. Ahn G.O., Brown J.M. Role of endothelial progenitors and other bone marrow-derived cells in the development of the tumor vasculature. Angiogenesis 2009, 12(2):159-164.
44. De Palma M., Naldini L. Role of haematopoietic cells and endothelial progenitors in tumour angiogenesis. Biochim Biophys Acta 2006, 1766(1):159-166.
45. van Ravenswaay Claasen H.H., Kluin P.M., Fleuren G.J. Tumor infiltrating cells in human cancer. On the possible role of CD16+ macrophages in antitumor cytotoxicity. Lab Invest 1992, 67(2):166-174.
46. Bingle L., Brown N.J., Lewis C.E. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002, 196(3):254-265.
47. Leek R.D., et al. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 1996, 56(20):4625-4629.
48. Tsutsui S., et al. Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep 2005, 14(2):425-431.
49. Ribatti D., et al. Macrophages and tumor angiogenesis. Leukemia 2007, 21(10):2085-2089.
50. Yang L., et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004, 6(4):409-421.
51. Movahedi K., et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008, 111(8):4233-4244.
52. Ostrand-Rosenberg S., Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009, 182(8):4499-4506.
53. Nagaraj S., et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007, 13(7):828-835.
54. Gabrilovich D.I., et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996, 2:1096-1103.
55. Dolcetti L., et al. Myeloid-derived suppressor cell role in tumor-related inflammation. Cancer Lett 2008, 267(2):216-225.
56. Gallina G., et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 2006, 116(10):2777-2790.
57. Bingisser R.M., et al. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J Immunol 1998, 160(12):5729-5734.
58. Shojaei F., et al. Role of myeloid cells in tumor angiogenesis and growth. Trends Cell Biol 2008, 18(8):372-378.
59. Yang L., et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008, 13(1):23-35.
60. Ferrara N. Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis. Curr Opin Hematol 2010, 17(3):219-224.
61. Tazzyman S., Lewis C.E., Murdoch C. Neutrophils: key mediators of tumour angiogenesis. Int J Exp Pathol 2009, 90(3):222-231.
62. Nielsen B.S., et al. 92kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. Int J Cancer 1996, 65(1):57-62.
63. Eck M., et al. Pleiotropic effects of CXC chemokines in gastric carcinoma: differences in CXCL8 and CXCL1 expression between diffuse and intestinal types of gastric carcinoma. Clin Exp Immunol 2003, 134(3):508-515.
64. Gijsbers K., et al. GCP-2/CXCL6 synergizes with other endothelial cell-derived chemokines in neutrophil mobilization and is associated with angiogenesis in gastrointestinal tumors. Exp Cell Res 2005, 303(2):331-342.
65. Benelli R., et al. Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation. FASEB J 2002, 16(2):267-269.
66. Nozawa H., Chiu C., Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA 2006, 103(33):12493-12498.
67. Looi L.M. Tumor-associated tissue eosinophilia in nasopharyngeal carcinoma. A pathologic study of 422 primary and 138 metastatic tumors. Cancer 1987, 59(3):466-470.
68. Salcedo R., et al. Eotaxin (CCL11) induces in vivo angiogenic responses by human CCR3+ endothelial cells. J Immunol 2001, 166(12):7571-7578.
69. Maltby S., Khazaie K., McNagny K.M. Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. Biochim Biophys Acta 2009, 1796(1):19-26.
70. Ribatti D., et al. The role of mast cells in tumour angiogenesis. Br J Haematol 2001, 115(3):514-521.
71. Starkey J.R., Crowle P.K., Taubenberger S. Mast-cell-deficient W/Wv mice exhibit a decreased rate of tumor angiogenesis. Int J Cancer 1988, 42(1):48-52. 0020-7136.
72. Theoharides T.C., et al. Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev 2007, 217:65-78.
73. Coquerelle C., Moser M. DC subsets in positive and negative regulation of immunity. Immunol Rev 2010, 234(1):317-334.
74. Curiel T.J., et al. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res 2004, 64(16):5535-5538.
75. Pietramaggiori G., et al. Tumors stimulate platelet delivery of angiogenic factors in vivo: an unexpected benefit. Am J Pathol 2008, 173(6):1609-1616.
76. Kepner N., Lipton A. A mitogenic factor for transformed fibroblasts from human platelets. Cancer Res 1981, 41(2):430-432.
77. Mohle R., et al. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 1997, 94(2):663-668.
78. Li J.J., et al. Thrombin induces the release of angiopoietin-1 from platelets. Thromb Haemost 2001, 85(2):204-206.
79. Wartiovaara U., et al. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost 1998, 80(1):171-175.
80. Salven P., Orpana A., Joensuu H. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res 1999, 5(3):487-491.
81. Italiano J.E., et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008, 111(3):1227-1233.
82. Salgado R., et al. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer 1999, 80(5-6):892-897.
83. Benoy I., et al. Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin Breast Cancer 2002, 2(4):311-315.
84. Verheul H.M., et al. Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood 2000, 96(13):4216-4221.
85. Boucharaba A., et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 2004, 114(12):1714-1725.
86. Ishii I., et al. Lysophospholipid receptors: signaling and biology. Annu Rev Biochem 2004, 73:321-354.
87. Kisucka J., et al. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci USA 2006, 103(4):855-860.
88. Goerge T., et al. Inflammation induces hemorrhage in thrombocytopenia. Blood 2008, 111(10):4958-4964.
89. Abramsson A., et al. Analysis of mural cell recruitment to tumor vessels. Circulation 2002, 105(1):112-117.
90. Morikawa S., et al. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002, 160(3):985-1000.
91. Evensen L., et al. Mural cell associated VEGF is required for organotypic vessel formation. PLoS ONE 2009, 4(6):e5798.
92. Gaengel K., et al. Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler Thromb Vasc Biol 2009, 29(5):630-638.
93. Song S., et al. PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 2005, 7(9):870-879.
94. Stagg J. Mesenchymal stem cells in cancer. Stem Cell Rev 2008, 4(2):119-124.
95. Pittenger M.F., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284(5411):143-147.
96. Prockop D.J. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997, 276(5309):71-74.
97. Nakamizo A., et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005, 65(8):3307-3318.
98. Studeny M., et al. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 2002, 62(13):3603-3608.
99. Mishra P.J., et al. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res 2008, 68(11):4331-4339.
100. Worthley D.L., et al. Human gastrointestinal neoplasia-associated myofibroblasts can develop from bone marrow-derived cells following allogeneic stem cell transplantation. Stem Cells 2009, 27(6):1463-1468.
101. Roorda B.D., et al. Bone marrow-derived cells and tumor growth: contribution of bone marrow-derived cells to tumor micro-environments with special focus on mesenchymal stem cells. Crit Rev Oncol Hematol 2009, 69(3):187-198.
102. Direkze N.C., et al. Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res 2004, 64(23):8492-8495.
103. Ramasamy R., et al. Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Leukemia 2007, 21(2):304-310.
104. Al-Khaldi A., et al. Postnatal bone marrow stromal cells elicit a potent VEGF-dependent neoangiogenic response in vivo. Gene Ther 2003, 10(8):621-629.
105. Kinnaird T., et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 2004, 94(5):678-685.
106. Nauta A.J., Fibbe W.E. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007, 110(10):3499-3506.
107. Djouad F., et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003, 102(10):3837-3844.
108. Coultas L., Chawengsaksophak K., Rossant J. Endothelial cells and VEGF in vascular development. Nature 2005, 438(7070):937-945.
109. Eichmann A., et al. Vascular development: from precursor cells to branched arterial and venous networks. Int J Dev Biol 2005, 49(2-3):259-267.
110. Salven P., et al. VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells. Blood 2003, 101(1):168-172.
111. Kovacic J.C., et al. Endothelial progenitor cells, angioblasts, and angiogenesis-old terms reconsidered from a current perspective. Trends Cardiovasc Med 2008, 18(2):45-51.
112. Dor Y., et al. Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 2004, 429(6987):41-46.
113. Barker N., et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007, 449(7165):1003-1007.
114. Blanpain C., et al. Self-renewal, multipotency, and the existence of two cell populations within an epithelial stem cell niche. Cell 2004, 118(5):635-648.
115. Bompais H., et al. Human endothelial cells derived from circulating progenitors display specific functional properties compared with mature vessel wall endothelial cells. Blood 2004, 103(7):2577-2584.
116. Timmermans F., et al. Endothelial outgrowth cells are not derived from CD133+ cells or CD45+ hematopoietic precursors. Arterioscler Thromb Vasc Biol 2007, 27(7):1572-1579.
117. Ingram D.A., et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 2004, 104(9):2752-2760.
118. Takakura N., et al. A role for hematopoietic stem cells in promoting angiogenesis. Cell 2000, 102(2):199-209.
119. Salven P., et al. Interleukin-1alpha promotes angiogenesis in vivo via VEGFR-2 pathway by inducing inflammatory cell VEGF synthesis and secretion. FASEB J 2002, 16(11):1471-1473.
120. Salven P., et al. Vascular endothelial growth factor in squamous cell head and neck carcinoma: expression and prognostic significance. Mod Pathol 1997, 10(11):1128-1133.
121. Salven P., Heikkila P., Joensuu H. Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br J Cancer 1997, 76(7):930-934.
122. Chi J.T., et al. Endothelial cell diversity revealed by global expression profiling. Proc Natl Acad Sci USA 2003, 100(19):10623-10628.